BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21159173)

  • 21. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The TP53 gene polymorphisms and survival of sporadic breast cancer patients.
    Bišof V; Salihović MP; Narančić NS; Skarić-Jurić T; Jakić-Razumović J; Janićijević B; Rudan P
    Med Oncol; 2012 Jun; 29(2):472-8. PubMed ID: 21365326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
    Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S; Staff S; Tanner M; Isola J
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: a single center experience.
    Tanriverdi O; Meydan N; Barutca S
    Asian Pac J Cancer Prev; 2014; 15(2):807-12. PubMed ID: 24568500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
    Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
    PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.
    Chen JQ; Litton J; Xiao L; Zhang HZ; Warneke CL; Wu Y; Shen X; Wu S; Sahin A; Katz R; Bondy M; Hortobagyi G; Berinstein NL; Murray JL; Radvanyi L
    Horm Cancer; 2010 Feb; 1(1):21-33. PubMed ID: 21761348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
    Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
    Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer.
    Yousef GM; Scorilas A; Nakamura T; Ellatif MA; Ponzone R; Biglia N; Maggiorotto F; Roagna R; Sismondi P; Diamandis EP
    Breast Cancer Res Treat; 2003 Mar; 78(2):149-58. PubMed ID: 12725415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Importance of PCNA proliferating fraction and histomorphologic prognostic factors for survival in breast cancer].
    Schönborn I; Minguillon C; Möhner M; Ebeling K
    Pathologe; 1993 Dec; 14(6):307-12. PubMed ID: 7907179
    [No Abstract]   [Full Text] [Related]  

  • 32. A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.
    Killian JK; Bilke S; Davis S; Walker RL; Jaeger E; Killian MS; Waterfall JJ; Bibikova M; Fan JB; Smith WI; Meltzer PS
    Am J Pathol; 2011 Jul; 179(1):55-65. PubMed ID: 21641572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
    Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
    IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
    Wolf B; Goebel G; Hackl H; Fiegl H
    BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
    Zhou Y; Simmons J; Jordan CD; Sonbol MB; Maihle N; Tang SC
    Clin Breast Cancer; 2019 Oct; 19(5):354-362.e7. PubMed ID: 31262687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case-control study of 87 cases.
    Genin AS; De Rycke Y; Stevens D; Donnadieu A; Langer A; Rouzier R; Lerebours F
    Breast; 2016 Dec; 30():222-227. PubMed ID: 26456897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and predictive value of PDL1 expression in breast cancer.
    Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F
    Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
    Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
    Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.
    Peurala H; Greco D; Heikkinen T; Kaur S; Bartkova J; Jamshidi M; Aittomäki K; Heikkilä P; Bartek J; Blomqvist C; Bützow R; Nevanlinna H
    PLoS One; 2011; 6(11):e26122. PubMed ID: 22102859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.